Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease

David Montani1,2,3,11, Edmund M. Lau1,2,3,11, Alexis Descatha4, Xavier Jais1,2,3, Laurent Savale1,2,3, Pascal Andujar5, Lynda Bensefa-Colas6, Barbara Girerd1,2,3, Inès Zendah7, Jerome Le Pavec9, Andrei Seferian1,2,3, Frédéric Perros1,2,3, Peter Dorfmüller1,3,8, Elie Fadel1,3,9, Florent Soubrier10, Oliver Sitbon1,2,3, Gérald Simonneau1,2,3 and Marc Humbert1,2,3

Affiliations: 1Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France. 2AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Service de Pneumologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France. 3UMR_S999, Université Paris-Sud, INSERM, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 4AP-HP UVSQ, Occupational Health Unit/Population-Based Epidemiological Cohorts Unit, UMS 011-UMR 1168, University Hospital of Poincaré, Garches, France. 5CHI Créteil, Service de Pneumologie et Pathologie professionnelle, Créteil, France. 6Paris Descartes University, Sorbonne Paris Cité, EA 4064, Laboratoire Santé Publique et Environnement, Occupational Diseases Dept, University Hospital of Centre of Paris COCHIN, AP-HP, Paris, France. 7Hôpital Abderrahmène Mami des Maladies Thoraciques, Pavillon I, Tunis, Tunisia. 8Service d’Anatomie Pathologique, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 9Service de Chirurgie Thoracique et Vasculaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 10UMR_S956, Université Pierre et Marie Curie-Paris 6, INSERM, Laboratoire d’Oncogénétique et Angiogénétique Moléculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. 11Both authors contributed equally to this work.

Correspondence: David Montani, Université Paris-Sud, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, Hôpital Bicêtre, 78, Rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France. E-mail: david.montani@bct.aphp.fr

ABSTRACT Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension characterised by predominant remodelling of pulmonary venules. Bi-allelic mutations in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene were recently described as the major cause of heritable PVOD, but risk factors associated with PVOD remain poorly understood. Occupational exposures have been proposed as a potential risk factor for PVOD, but epidemiological studies are lacking.

A case–control study was conducted in consecutive PVOD (cases, n=33) and pulmonary arterial hypertension patients (controls, n=65). Occupational exposure was evaluated via questionnaire interview with blinded assessments using an expert consensus approach and a job exposure matrix (JEM). Using the expert consensus approach, PVOD was significantly associated with occupational exposure to organic solvents (adjusted OR 12.8, 95% CI 2.7–60.8), with trichloroethylene being the main agent implicated (adjusted OR 8.2, 95% CI 1.4–49.4). JEM analysis independently confirmed the association between PVOD and trichloroethylene exposure. Absence of significant trichloroethylene exposure was associated with a younger age of disease (54.8±21.4 years, p=0.037) and a high prevalence of harbouring bi-allelic EIF2AK4 mutations (41.7% versus 0%, p=0.015).

Occupational exposure to organic solvents may represent a novel risk factor for PVOD. Genetic background and environmental exposure appear to influence the phenotypic expression of the disease.

@ERSpublications
Occupational exposure to organic solvents is a novel risk factor for pulmonary veno-occlusive disease http://ow.ly/StFsk
Introduction
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) characterised by progressive occlusion of pulmonary veins by fibrous tissue and intimal thickening, with preferential involvement of venules and small veins within the lobular septa [1, 2]. In the current PH classification, PVOD and pulmonary capillary haemangiomatosis (PCH) are classified together as a unified entity as Group 1 PVOD/PCH, as both conditions share overlapping clinical, histopathological and genetic features, and are considered to represent spectrums of a common disorder [3, 4].

The pathogenesis and risk factors associated with the development of PVOD remain poorly understood. Recently, autosomal recessive bi-allelic mutations in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene have been identified as the major genetic cause of PVOD/PCH [5, 6]. EIF2AK4 bi-allelic mutations were identified in all patients with heritable forms of PVOD from the French PH Network and, interestingly, ∼25% of apparently sporadic cases of PVOD were also found to carry bi-allelic EIF2AK4 mutations.

Apart from genetic predisposition, other risk factors have also been identified to be associated with PVOD [7]. These include smoking [8], chemotherapeutic agents (particularly alkylating agents) [9, 10] and connective tissue diseases [11]. Indeed, pulmonary venous involvement is frequently observed in PH associated with connective tissue diseases [12–14] and as many as 60% of patients with systemic sclerosis-associated pre-capillary PH may display clinical features consistent with PVOD [13].

Chemical exposure has previously been proposed to be a potential aetiologial factor, with case reports suggesting the development of PVOD following various occupational exposures [1, 11]. Accordingly, we have also observed from our clinical experience that some PVOD patients report an occupational history of significant exposure to chemicals such as organic solvents. Furthermore, numerous epidemiological studies have demonstrated an association between exposure to organic solvents and systemic sclerosis [15–17]. Given the above considerations and the aforementioned high frequency of venular involvement in systemic sclerosis-associated pre-capillary PH, we speculated whether occupational exposure to organic solvents might also be relevant in PVOD.

The aim of the present study was to perform a case–control study to evaluate the association between PVOD and occupational exposure to chemicals, particularly organic solvents. Moreover, we were interested to assess whether genetic factors had a modifying effect on this potential association.

Methods
Study population
This was a case–control study conducted at the National Reference Centre for Severe Pulmonary Hypertension, Le Kremlin Bicêtre, France. Between September 2008 and February 2010, patients above the age of 18 with a diagnosis of PVOD (cases) and idiopathic, anorexigen-induced or heritable pulmonary arterial hypertension (PAH) (controls) were eligible for study participation. To avoid selection bias, consecutive consenting patients with a diagnosis of PVOD or PAH who presented to the outpatient clinic for routine follow-up assessment were invited to participate.

The diagnosis of PAH was made according to current guidelines [18] and all patients had confirmed pre-capillary PH at diagnostic right heart catheterisation. The diagnosis of PVOD was established according to the following criteria and only patients with either confirmed or highly probable PVOD were recruited. Patients were considered to have confirmed PVOD if a histological specimen (from either lung biopsy, explanted lung or post mortem examination) was consistent with PVOD or they were carriers of bi-allelic mutations in the EIF2AK4 gene. Patients were also deemed to have confirmed PVOD if they presented with highly probable PVOD and developed pulmonary oedema following the initiation of specific PAH therapy.

Highly probable PVOD was considered to be present if patients fulfilled at least two of the following three criteria: 1) two or more characteristic radiological signs of PVOD (septal lines, centrilobular ground glass opacities, enlarged mediastinal lymph nodes) on high-resolution computed tomography (HRCT) of the chest, 2) diffusing capacity of the lung for carbon monoxide to alveolar volume ratio (D LCO/VA) <55% or resting arterial oxygen tension (PaO2) on room air <65 mmHg or 3) presence of alveolar haemorrhage on bronchoalveolar lavage (Golde score >80 or haemosiderin-laden macrophages >30%). As ante mortem diagnosis of PVOD with lung biopsy is not usually feasible due to the presence of severe PH, we have previously demonstrated that a noninvasive diagnostic approach based on the above criteria is highly specific for PVOD [1, 8]. Exclusion criteria for both cases and controls included a history of connective tissue disease, portal hypertension, HIV infection, congenital heart disease and thromboembolic disease.

Clinical characteristics of all study subjects, including baseline demographic information, pulmonary haemodynamics, New York Heart Association Functional Class (NYHA FC), 6-min walk distance (6MWD) and lung function testing, were retrieved from the Registry of the French PH Network. This Registry was
established in accordance with French bioethics laws (Commission Nationale de l’Informatique et des Libertés) and all patients gave informed consent.

Genetic analysis
Genetic counselling and testing were proposed to both PVOD and PAH patients. PAH and PVOD patients were screened for point mutations and large rearrangements of the bone morphogenetic protein receptor type 2 (BMPR2) gene, the main predisposing factor for heritable PAH. Patients with confirmed or highly probable PVOD were also screened for EIF2AK4 mutations. In the French Referral Centre, BMPR2 mutation testing has been conducted since 2003 and EIF2AK4 mutation testing began in 2013 following the first report of bi-allelic mutations in the EIF2AK4 gene as a cause of heritable PVOD. Eight PVOD patients died before DNA collection was possible for EIF2AK4 testing. Genetic analyses of BMPR2 and EIF2AK4 genes were performed as previously described [5, 19]. All patients undergoing genetic testing provided written informed consent.

Occupational exposure questionnaire
Each subject’s work history was determined by means of a standardised occupational questionnaire conducted by an experienced interviewer. The questionnaire was designed by a PH physician (D.M.) together with an occupational medicine physician (A.D.). Each job lasting for a period of at least 3 months was recorded, and details included the job title, activity sector and associated tasks. Information on specific job tasks included a complete description of the frequency and duration of the task, the use of protection devices, and direct or indirect exposure to chemicals, dusts, gases or fumes. Subjects were also asked to self-report whether they had specific work or leisure exposure to the following substances: any organic solvents, trichloroethylene, paints, varnish, glues, degreasing agents, plastic resins, detergents, disinfectants, cosmetic products, insecticides, herbicides, epoxy derivatives and silica.

Expert consensus assessment
In the primary analysis, an expert consensus approach was employed and three occupational medicine physicians (A.D., P.A. and L.B.) blinded to the case or control status of study subjects reviewed each questionnaire. For each job suspected to be associated with a specific exposure, the duration of exposure (number of years) was determined. Recent exposures (<10 years from date of diagnosis) were considered separately, considering plausible latency between exposure and disease development. Weighting factors were attributed for the intensity of exposure (low, intermediate or high level) and the frequency of exposure (sporadic, regular but not often (<25% of the working day) and often (≥25% of the working day)). A semi-quantitative exposure category was then built for the assessment of cumulative exposure level: 0, unexposed; 1, trivial; 2, moderate; 3, high. From this expert consensus approach, an exposure category of 2 or more was considered to be indicative of positive exposure.

Job exposure matrix assessment
A job exposure matrix (JEM) was also used to evaluate occupational exposures (Matgéné) [20, 21]. Both expert consensus assessment and JEM are commonly used to evaluate occupational exposures [20, 22, 23]. Therefore, these two independent assessment tools were used as complementary analyses to increase the robustness of any positive associations. For JEM analysis, occupations and activity sectors were coded according to the French “Professions et Categories Socioprofessionelles” (1994) and “Nomenclature d’Activités Francaise” (2000). Based on the individual occupation and activity sector, the JEM enables an estimation of cumulative exposure to specific solvent classes (trichloroethylene, white spirits, benzene and aliphatic petroleum solvents). For each solvent class, the JEM provides information on the probability, intensity and frequency of exposure associated with each job. From the JEM, scores were assigned for the probability, intensity and frequency of exposure (1, low; 2, moderate; 3, high). A cumulative exposure index score (CEI) was constructed from the JEM as follows: CEI=probability×intensity×frequency×duration (years). For example, a job considered to have a low probability (score 1), low intensity (score 1) and high frequency (score 3) of exposure to trichloroethylene with a duration of 5 years will have a CEI=1x1x3x5=15. A CEI >10 was considered to be indicative of positive exposure. CEI was calculated with and without adjusting for recent exposure (<10 years from diagnosis). The date of diagnosis was considered to be the date of diagnostic right heart catheterisation.

Statistical analysis
Results are presented as mean±SD unless otherwise stated. Continuous variables were compared with independent sample t-test or Mann–Whitney U-test, as appropriate. Proportions were compared using Chi-squared and Fisher’s exact tests. Unconditional logistical regression analyses were performed to assess the association between occupation exposures and PVOD, with multivariate analysis adjusting for the presence of confounding factors. Statistical significance was inferred at p<0.05 and all analysis were performed using SPSS version 22 (IBM, Chicago, IL, USA).
Results

Patients

A total of 100 consecutive subjects were recruited (PVOD, n=34; PAH, n=66) and underwent detailed occupational exposure assessment. However, during the course of the study two patients with an initial classification of PVOD and PAH had alternative final diagnoses (systemic sclerosis, n=1 and portal hypertension, n=1, respectively), resulting in a total of 33 PVOD and 65 PAH patients included in the final analysis.

PVOD patients were older compared with PAH patients (60.4±18.1 versus 50.6±15.8 years, p=0.0072), and a bimodal age distribution was seen in the PVOD group with two apparent peaks occurring at the 20–30 and 70–80 years deciles (figure 1). The younger peak was predominantly represented by patients with heritable PVOD (n=5) harbouring bi-allelic mutations in the EIF2AK4 gene including a mean of age 26.1±3.6 years and a sex ratio (male:female) of 3:2. In contrast, the PAH group displayed a unimodal age distribution peaking at the 50–60 years decile.

Compared with PAH, a higher male:female ratio was found in the PVOD group (4.5 versus 0.4, p<0.001). PVOD patients also had a higher prevalence of significant smoking history of >5 pack-years (78.8% versus 32.3%, p<0.001) as well as higher cumulative smoking exposure (33.0±24.7 versus 8.0±14.3 pack-years, p<0.0001). The association between PVOD and smoking remained significant after adjustment for age and sex.

PVOD patients also had a higher prevalence of significant smoking history of >5 pack-years (78.8% versus 32.3%, p<0.001) as well as higher cumulative smoking exposure (33.0±24.7 versus 8.0±14.3 pack-years, p<0.0001). The association between PVOD and smoking remained significant after adjustment for age and sex.

PVOD patients presented with more severe functional impairment as evidenced by lower 6MWD (226±166 versus 353±137 m, p=0.002) and higher NYHA FC (p=0.082), despite less severe haemodynamic impairment at diagnosis compared with PAH patients. Table 1 summarises the baseline characteristics of the study population.

Expert consensus assessment of occupational exposure

From the primary expert consensus assessment, a significant occupational history of exposure was elicited in 72.7% of PVOD patients compared with 27.7% of PAH patients (p<0.001). When analysis was stratified by male sex only, the association between occupational exposure and PVOD remained significant (74.1% versus 25.9%, p=0.016) (figure 2a and b). Of the PVOD patients with a significant exposure history, the most common occupational exposures included any organic solvents (79.2%), including trichloroethylene (58.3%), degreasing agents (29.2%), paints (25.0%) and varnish/glue (25%) (figure 3).

Table 2 summarises the association between exposure to specific agents and PVOD. Following adjustment for age, sex and smoking history, both organic solvents and trichloroethylene exposure remained significantly associated with PVOD (adjusted OR for organic solvents 12.8, 95% CI 2.7–60.8; p=0.001 and adjusted OR for trichloroethylene 8.2, 95% CI 1.4–49.4; p=0.022). The median latency between first exposure to trichloroethylene and PVOD diagnosis was 48 years (interquartile range (IQR) 39–52) with a median exposure duration of 17 years (IQR 9–33). The most common occupations resulting in trichloroethylene exposure included metal workers, mechanics and repairers, building painters, and cleaners.

FIGURE 1 Age distribution of a) pulmonary veno-occlusive disease (PVOD; n=33) and b) pulmonary arterial hypertension (PAH; n=65) patients. PVOD patients displayed a bimodal distribution with the first peak occurring at the 20–30 years decile and a later peak at the 70–80 years decile. The first peak corresponded mainly to patients with heritable PVOD carrying bi-allelic mutations in the eukaryotic translation initiation factor 2a kinase 4 (EIF2AK4) gene. In contrast, a unimodal age distribution peaking at the 50–60 years decile was observed in the PAH group.

DOI: 10.1183/13993003.00814-2015
Job exposure matrix assessment

Table 3 summarises the association between PVOD and exposure to four groups of solvents (trichloroethylene, white spirits, benzene and petroleum solvents) using the JEM approach. Trichloroethylene was the only solvent that was significantly associated with PVOD, with and without adjustment for recent exposure (adjusted OR 80.72% or n (%), unless otherwise stated. PAH: pulmonary arterial hypertension; PVOD: pulmonary veno-occlusive disease; NYHA FC: New York Heart Association Functional Class; 6MWD: 6-min walk distance; mPAP: mean pulmonary artery pressure; CI: cardiac index; RAP: right arterial pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; $D_{LCO}/V_{A}$: diffusing capacity for carbon monoxide to alveolar volume ratio; % pred: % predicted; BMPR2: bone morphogenetic protein receptor type 2; EIF2AK4: eukaryotic translation initiation factor 2α kinase 4.

**FIGURE 2** Proportion of patients with a significant history of occupational exposures. a) Compared with pulmonary arterial hypertension (PAH), a higher proportion of pulmonary veno-occlusive disease (PVOD) patients had a documented history of occupational exposures (PAH, n=65; PVOD, n=33). b) The relationship remained significant when analysis was stratified by male sex only (PAH, n=20; PVOD, n=27).
9.8, 95% CI 1.5–62.3 and 6.4, 95% CI 1.3–30.4, respectively; both \( p < 0.05 \). The agreement between expert consensus assessment and JEM assessment of exposure to trichloroethylene had a \( \kappa \)-value of 0.61.

**Relationship between EIF2AK4 mutation and occupational exposure**

Genetic results were available in 88 (89.8%) patients within the entire study cohort (EIF2AK4 mutations screening in 75.8% of the PVOD group and BMPR2 status in 96.9% of the PAH group). Five out of 25 (20.0%) PVOD patients carried bi-allelic mutations in the EIF2AK4 gene, of which two had a familial history of PVOD. No PVOD patients tested positive for the BMPR2 mutation. For the PAH group, 16 out of 63 (25.4%) harboured heterozygous mutation in the BMPR2 gene (table 1).

As trichloroethylene was the main aetiological agent associated with PVOD identified from both the expert consensus and JEM assessments, we explored whether there were any phenotypic differences in PVOD patients with and without a history of significant exposure to trichloroethylene. PVOD patients who were not significantly exposed to trichloroethylene were younger (54.8±21.4 versus 67.9±8.1 years, \( p = 0.037 \)) and, importantly, they were more likely to harbour EIF2AK4 mutations (41.7% versus 0%, \( p = 0.015 \)). No significant differences in haemodynamics or functional capacity were seen between the trichloroethylene exposed and nonexposed groups. Table 4 summarises the characteristics of PVOD patients stratified by exposure to trichloroethylene.

**TABLE 2 Expert consensus assessment of common occupational exposures**

<table>
<thead>
<tr>
<th>Subjects n</th>
<th>PAH</th>
<th>PVOD</th>
<th>Crude OR (95% CI)</th>
<th>p-value</th>
<th>Adjusted OR # (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any solvents</td>
<td>4 (6.2)</td>
<td>19 (57.6)</td>
<td>23.5 [6.1–70.4]</td>
<td>&lt;0.0001</td>
<td>12.8 [2.7–60.8]</td>
<td>0.001</td>
</tr>
<tr>
<td>Trichloroethylene</td>
<td>2 (3.1)</td>
<td>14 (42.4)</td>
<td>23.2 [4.8–111.3]</td>
<td>&lt;0.0001</td>
<td>8.2 [1.6–49.4]</td>
<td>0.022</td>
</tr>
<tr>
<td>Paint</td>
<td>2 (3.1)</td>
<td>6 (18.2)</td>
<td>7.0 [1.3–36.9]</td>
<td>0.022</td>
<td>1.7 [0.3–10.9]</td>
<td>0.591</td>
</tr>
<tr>
<td>Varnish/glue</td>
<td>2 (3.1)</td>
<td>6 (18.2)</td>
<td>7.0 [1.3–36.9]</td>
<td>0.022</td>
<td>2.5 [0.3–21.3]</td>
<td>0.398</td>
</tr>
<tr>
<td>Detergents</td>
<td>9 (13.8)</td>
<td>3 (9.1)</td>
<td>0.62 [0.16–2.47]</td>
<td>0.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Degreasing agent</td>
<td>0 (0)</td>
<td>7 (21.2)</td>
<td>Not estimated</td>
<td>0.0003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cosmetic products</td>
<td>2 (3.1)</td>
<td>1 (3.0)</td>
<td>0.98 [0.09–11.3]</td>
<td>0.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleach</td>
<td>6 (9.2)</td>
<td>2 (6.1)</td>
<td>0.63 [0.1–3.3]</td>
<td>0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kerosene</td>
<td>0 (0)</td>
<td>3 (9.1)</td>
<td>Not estimated</td>
<td>0.036</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welding fumes</td>
<td>0 (0)</td>
<td>4 (12.1)</td>
<td>Not estimated</td>
<td>0.011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insecticides/herbicides</td>
<td>2 (3.1)</td>
<td>1 (3.0)</td>
<td>0.98 [0.09–11.3]</td>
<td>0.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epoxy derivatives</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>Not estimated</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silica</td>
<td>0 (0)</td>
<td>4 (12.1)</td>
<td>Not estimated</td>
<td>0.011</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as n [%], unless otherwise stated. PAH: pulmonary arterial hypertension; PVOD: pulmonary veno-occlusive disease. #: adjusted for age, sex and smoking history (pack-years).
Pathologic assessment of PVOD patients with occupational exposure

Histologic specimens were available for analysis in seven PVOD patients, including one patient with a history of positive exposure to trichloroethylene. This patient demonstrated venular, capillary and arterial lesions that were typical of PVOD, undistinguishable from idiopathic or heritable PVOD (figure 4).

<table>
<thead>
<tr>
<th>TABLE 3 Association between pulmonary veno-occlusive disease (PVOD) and different solvent classes using the job exposure matrix</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAH</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>Subjects n</td>
</tr>
<tr>
<td>Trichloroethylene</td>
</tr>
<tr>
<td>Lifetime exposure</td>
</tr>
<tr>
<td>10-year lag exposure</td>
</tr>
<tr>
<td>White spirits</td>
</tr>
<tr>
<td>Lifetime exposure</td>
</tr>
<tr>
<td>10-year lag exposure</td>
</tr>
<tr>
<td>Benzene</td>
</tr>
<tr>
<td>Lifetime exposure</td>
</tr>
<tr>
<td>10-year lag exposure</td>
</tr>
<tr>
<td>Petroleum solvents</td>
</tr>
<tr>
<td>Lifetime exposure</td>
</tr>
<tr>
<td>10-year lag exposure</td>
</tr>
</tbody>
</table>

Data are presented as n (%), unless otherwise stated. PAH: pulmonary arterial hypertension. *: adjusted for age, sex and smoking history (pack-years).

TABLE 4 Characteristics of pulmonary veno-occlusive disease (PVOD) patients with and without significant exposure to trichloroethylene#

<table>
<thead>
<tr>
<th>Subjects n</th>
<th>Absent or trivial exposure</th>
<th>Intermediate or high exposure</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age years</td>
<td>54.8±21.4</td>
<td>67.9±8.1</td>
<td>0.037</td>
</tr>
<tr>
<td>Female/male</td>
<td>6/13</td>
<td>0/14</td>
<td>0.027</td>
</tr>
<tr>
<td>Tobacco exposure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never-smoker</td>
<td>5 (26.3)</td>
<td>0 [0]</td>
<td>0.057</td>
</tr>
<tr>
<td>Current smoker</td>
<td>3 (15.8)</td>
<td>1 (7.1)</td>
<td>0.62</td>
</tr>
<tr>
<td>&gt;5 pack-years</td>
<td>13 (68.4)</td>
<td>13 (92.9)</td>
<td>0.20</td>
</tr>
<tr>
<td>Total exposure pack-years</td>
<td>29.0±26.0</td>
<td>38.4±22.4</td>
<td>0.29</td>
</tr>
<tr>
<td>NYHA FC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>1 (5.2)</td>
<td>1 (7.1)</td>
<td>1.0</td>
</tr>
<tr>
<td>III/IV</td>
<td>18 (94.7)</td>
<td>13 (92.9)</td>
<td></td>
</tr>
<tr>
<td>6MWD m</td>
<td>301±146</td>
<td>245±110</td>
<td>0.36</td>
</tr>
<tr>
<td>Haemodynamics and gas transfer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mPAP mmHg</td>
<td>48.1±10.0</td>
<td>51.2±13.5</td>
<td>0.44</td>
</tr>
<tr>
<td>CI L·min⁻¹·m⁻²</td>
<td>2.3±0.7</td>
<td>2.6±0.7</td>
<td>0.29</td>
</tr>
<tr>
<td>RAP mmHg</td>
<td>8.4±5.5</td>
<td>11.5±6.8</td>
<td>0.16</td>
</tr>
<tr>
<td>PAWP mmHg</td>
<td>10.3±3.6</td>
<td>9.8±3.2</td>
<td>0.70</td>
</tr>
<tr>
<td>PVR WU</td>
<td>9.7±3.7</td>
<td>9.2±4.9</td>
<td>0.71</td>
</tr>
<tr>
<td>DLCO/VA % pred</td>
<td>34.4±11.8</td>
<td>37.8±14.4</td>
<td>0.49</td>
</tr>
<tr>
<td>EIF2AK4 mutations¶</td>
<td>5/12 (41.7)</td>
<td>0/13 (0)</td>
<td>0.015</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD or n (%), unless otherwise stated. NYHA FC: New York Heart Association Functional Class; 6MWD: 6-min walk distance; mPAP: mean pulmonary artery pressure; CI: cardiac index; RAP: right arterial pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; DLCO/VA: diffusing capacity for carbon monoxide to alveolar volume ratio; % pred: % predicted; EIF2AK4: eukaryotic translation initiation factor 2α kinase 4. #: exposure level was based on expert consensus assessment; ¶: EIF2AK4 mutation testing was available in 25 out of 33 PVOD patients [absent or trivial exposure, n=12; moderate or high exposure, n=13].

DOI: 10.1183/13993003.00814-2015
Discussion

To the best of our knowledge, the present study represents the largest series of PVOD patients to be reported and is the first to systematically evaluate occupational exposures as a potential risk factor for PVOD using detailed questionnaire interview. We identified an association between occupational exposure to organic solvents and PVOD, with trichloroethylene (a chlorinated solvent) being the main agent implicated in this association. This association was found using two independent methods of exposure assessment, i.e. expert consensus approach and JEM. Moreover, we found distinct phenotypic differences in PVOD patients with and without a history of exposure. Compared with PVOD patients with a history of exposure to trichloroethylene, unexposed patients were younger and had a higher prevalence of harbouring bi-allelic mutations in the EIF2AK4 gene. These findings offer novel insights into the risk factors and pathobiology of PVOD.

PVOD is a rare form of PH with an estimated annual incidence rate of \( \sim 0.1–0.2 \) per million [1, 11]. The defining pathological feature of PVOD is the diffuse involvement of venules and septal veins in a vasculopathy characterised by intimal fibrosis resulting in luminal narrowing or obliteration [2]. The clinical presentation of PVOD can mimic PAH with insidious onset of breathlessness and signs of PH. Compared with PAH, the clinical course of PVOD is usually more aggressive and is characterised by poor response to PAH therapy. In fact, the use of pulmonary vasodilators can be associated with the development of life-threatening pulmonary oedema. Lung transplantation remains the preferred therapy for eligible PVOD patients [1].

Chlorinated organic solvents have been associated with numerous adverse health effects, including acute and chronic neurotoxicity, hepatitis, renal injury, dermatitis haematological effects, and lung cancer [24–26]. Furthermore, solvent exposure has been linked in epidemiological studies to the development of systemic sclerosis, a known cause of PVOD. Although conflicting results have been reported in the literature, a meta-analysis pooling data from 11 studies (1291 patients and 3435 controls) demonstrated a significant association between solvent exposure and systemic sclerosis with an increased OR of 1.8 (95% CI 1.2–2.5; \( p=0.002 \)) [27]. Furthermore, a previous study by Niertart et al. [16] found that trichloroethylene was a
particular risk factor for systemic sclerosis in male patients, especially in those with serological evidence of
topoisonerase 1 antibodies. Pre-capillary PH is a lethal complication of systemic sclerosis with a lifetime risk
of ∼10% [28]. Although most cases of pre-capillary PH in systemic sclerosis are attributed as PAH, emerging
evidence suggests that pulmonary venous involvement presenting as PVOD is an under-recognised
complication [13]. In addition, a recent study highlighted that the majority of patients with systemic sclerosis
associated pre-capillary PH demonstrate characteristic radiological features of PVOD on chest HRCT [14]. It
remains entirely speculative whether PVOD and systemic sclerosis might represent different spectrums of
potential end-organ toxicities associated with organic solvent exposure.

The epidemiology and risk factors associated with the development of PVOD remain poorly understood.
The largest series of PVOD patients published to date included only 24 patients [8]. Previous studies have
indicated that exposure to toxins such as cigarette smoke and chemotherapeutic agents is associated with
the development of PVOD [8, 9]. The association between smoking and PVOD was confirmed in this
study. It is believed that pulmonary endothelial injury is perhaps the common inciting event that underlies
the association between toxic exposures and PVOD. However, very little is known regarding the effects of
solvents such as trichloroethylene on endothelial cell function. A study by Ou et al. [29] showed that in
bovine coronary endothelial cells, trichloroethylene altered endothelial nitric oxide synthase (eNOS) activity
and induced eNOS to shift from nitric oxide to superoxide anion generation. However, even if endothelial
injury does represent a common mechanistic pathway of toxin exposures, it is unknown why there might be
a predilection for pulmonary venular injury rather than arterial injury for these specific exposures.

Recently, bi-allelic mutations in the EIF2AK4 gene coding for a serine/threonine-protein kinase, also
known as general control nonderepressible 2 (GCN2), were found to be the major cause of heritable
PVOD [5]. GCN2 is a member of a family of eukaryotic initiation factor 2 kinases that become activated
in response to diverse cellular stresses. Upon amino acid starvation, GCN2 phosphorylates eukaryotic
initiation factor 2, which leads to preferential synthesis of stress proteins [30]. It remains elusive on how
loss-of-function mutations in the EIF2AK4 gene are related to pulmonary vascular remodelling and how
GCN2 influences vascular homeostasis in different vascular compartments such as arteries or veins.

GCN2 appears important in protecting against liver injury induced by carbon tetrachloride, a chlorinated
industrial solvent related to trichloroethylene. GCN2 knockout mice (GCN2−/−) are more susceptible to acute
and chronic liver toxicity induced by carbon tetrachloride and increased oxidative stress appears to be a
potentially relevant mechanism [31]. GCN2−/− animals have lower levels of glutathione peroxidase in the
liver [32] and GCN2 activation has antioxidant effects on hepatocytes leading to a decrease in hydrogen
peroxide levels [33]. It is of interest that mice exposed to trichloroethylene inhalation demonstrate lung injury
with vacuolation of club cells and marked thickening of the capillary endothelium accompanied by a fall in
reduced glutathionine content together with a concomitant increase in oxidised glutathionine, which are
indicative of oxidative stress [34]. Oxidative stress is known to play a role in vascular remodelling, including
PH [35, 36], and might represent an important mechanistic pathway for the development of PVOD. It
remains unknown whether environmental exposures to toxins such as cigarette smoke or trichloroethylene
have an effect of lung vascular GCN2 function and this should be explored further in animal studies.

Our present study also provides important insights into the potential interaction between gene and environment
in the phenotypic manifestation of PVOD. One phenotype appears to be characterised by an older age of
disease onset, positive exposure history and absence of EIF2AK4 mutations. In contrast, patients without a
history of exposure are younger at diagnosis with a high prevalence of heritable disease. It should be emphasised
that the absolute risk of developing PVOD associated with organic solvents and trichloroethylene exposure
remains small, as these agents are widely used in many industrial sectors and PVOD remains a rare disease.
Individual susceptibility must be important and it is known that polymorphisms in cytochrome P450 (CYP2E1)
 affect metabolism of trichloroethylene, possibly influencing susceptibility to trichloroethylene-induced toxicity in
humans [37]. Finally, the long latency between initial exposure to trichloroethylene and the development of
clinically overt PVOD among certain patients suggests that chronic and repeated exposure is probably necessary
to induce significant pulmonary venous remodelling.

**Study limitations**

Although our study may be considered to be relatively small, PVOD is a rare disease and highly significant
associations were found with organic solvents and trichloroethylene exposure, with the acknowledgement
that confidence limits of odds ratios were wide due to our sample size. As with all case-control studies,
assessment of exposure is subject to recall bias and does not provide any proof of causality between the
exposure and disease. Reliable exposure assessment can also be challenging and several methods are
available to estimate exposure retrospectively. Therefore, we utilised two separate methods (i.e., expert
consensus approach and JEM) to assess occupational exposure in order to increase the robustness of our
findings. Although the agreement between the two methods was moderate to good, this is consistent with

DOI: 10.1183/13993003.00814-2015
published studies which have also demonstrated moderate agreement when different exposure assessment methodologies are employed [22, 23]. It should be viewed as reassuring that a positive association between trichloroethylene and PVOD was demonstrated using two independent assessment tools.

PAH patients were younger and had a higher proportion of females, which may bias towards a reduced probability of relevant occupational exposures. However, PVOD remained significantly associated with organic solvents and trichloroethylene after adjustment for age, sex and smoking history. The addition of a population-level control group may also strengthen the findings of our study. At present, no financial compensation has been proposed to exposed patients with PVOD in France and the study was conducted with the understanding that patients will not derive direct benefits from participation. Therefore, it is unlikely that financial motivation or secondary gain would have resulted in reporting bias.

Conclusions
We demonstrate that occupational exposure to organic solvent and trichloroethylene is associated with PVOD. Genetic background and environmental exposure appear to influence the phenotypic expression of the disease. Clinicians should obtain a detailed history of exposure to organic solvents, particularly trichloroethylene.

References